Chitsaz Ahmad, Najafi Mohammad Reza, Habibi Farzaneh, Amirhajloo Sajad
Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Department of Statistics, Isfahan University of Technology, Isfahan, Iran.
Curr J Neurol. 2024 Jan 5;23(1):39-43. doi: 10.18502/cjn.v23i1.16431.
A large percentage of patients with Parkinson's disease (PD) suffer from excessive daytime sleepiness (EDS). This study aims to compare the effectiveness of modafinil and methylphenidate on EDS and side effects. Fifty nine patients with PD and EDS [Epworth Sleepiness Scale (ESS) more than 9] were recruited in a double-blind placebo controlled trial. Twenty-two patients received modafinil 200 mg daily, twenty-six patients received methylphenidate 10 mg daily, and 11 patients received placebo for 6 weeks. Pittsburgh Sleep Quality Index (PSQI) and ESS were filled out at baseline and 6 weeks later. There was no significant difference in demographics, PSQI, and ESS variables at baseline. The mean of ESS scores decreased significantly in modafinil (17.36 ± 5.05 vs. 10.55 ± 4.62, P 0.001 and methylphenidate (16.27 ± 5.40 vs. 12.23 ± 6.28, P < 0.001) groups after 6-week trial, compared with control group (14.27 ± 4.49 vs. 14.09 ± 4.46, P = 0.710). The effectiveness of modafinil and methylphenidate on improving daytime sleepiness and night sleep of patients was not significantly different. Both modafinil and methylphenidate were effective drugs in improving EDS and quality of sleep without significant difference in efficiency and side effects.
很大比例的帕金森病（PD）患者存在日间过度嗜睡（EDS）。本研究旨在比较莫达非尼和哌甲酯对EDS的疗效及副作用。在一项双盲安慰剂对照试验中招募了59例患有PD和EDS[爱泼华嗜睡量表（ESS）大于9]的患者。22例患者每日服用200毫克莫达非尼，26例患者每日服用10毫克哌甲酯，11例患者服用安慰剂，为期6周。在基线期和6周后填写匹兹堡睡眠质量指数（PSQI）和ESS。基线期时，人口统计学、PSQI和ESS变量无显著差异。6周试验后，与对照组（14.27±4.49对14.09±4.46，P=0.710）相比，莫达非尼组（17.36±5.05对10.55±4.62，P<0.001）和哌甲酯组（16.27±5.40对12.23±6.28，P<0.001）的ESS评分均值显著降低。莫达非尼和哌甲酯在改善患者日间嗜睡和夜间睡眠方面的疗效无显著差异。莫达非尼和哌甲酯都是改善EDS和睡眠质量的有效药物，在疗效和副作用方面无显著差异。
